Patents by Inventor Alazar N. Ghebremeskel

Alazar N. Ghebremeskel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210169780
    Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.
    Type: Application
    Filed: October 23, 2020
    Publication date: June 10, 2021
    Inventors: Michael R. Robinson, James A. Burke, Rhett M. Schiffman, Alazar N. Ghebremeskel
  • Publication number: 20210161809
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
    Type: Application
    Filed: November 6, 2020
    Publication date: June 3, 2021
    Inventors: Lon T. Spada, Alazar N. Ghebremeskel, Michael R. Robinson
  • Publication number: 20210030766
    Abstract: Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.
    Type: Application
    Filed: March 27, 2020
    Publication date: February 4, 2021
    Inventors: Alazar N. Ghebremeskel, Michael R. Robinson
  • Patent number: 10842739
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: November 24, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Lon T. Spada, Alazar N. Ghebremeskel, Michael R. Robinson
  • Publication number: 20200121593
    Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.
    Type: Application
    Filed: December 18, 2019
    Publication date: April 23, 2020
    Inventors: Michael R. Robinson, James A. Burke, Rhett M. Schiffman, Alazar N. Ghebremeskel
  • Publication number: 20200069847
    Abstract: Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.
    Type: Application
    Filed: November 4, 2019
    Publication date: March 5, 2020
    Inventors: Michael R. Robinson, Hui Liu, Patrick M. Hughes, Lon Spada, Alazar N. Ghebremeskel
  • Publication number: 20200069578
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
    Type: Application
    Filed: November 11, 2019
    Publication date: March 5, 2020
    Inventors: Lon T. Spada, Alazar N. Ghebremeskel, Michael R. Robinson
  • Patent number: 10471004
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: November 12, 2019
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, Alazar N. Ghebremeskel, Michael R. Robinson
  • Patent number: 10463772
    Abstract: Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: November 5, 2019
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, Hui Liu, Patrick M. Hughes, Lon T. Spada, Alazar N. Ghebremeskel
  • Publication number: 20190254965
    Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.
    Type: Application
    Filed: May 6, 2019
    Publication date: August 22, 2019
    Inventors: Michael R. Robinson, James A. Burke, Rhett M. Schiffman, Alazar N. Ghebremeskel
  • Patent number: 10278919
    Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: May 7, 2019
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, James A. Burke, Rhett M Schiffman, Alazar N. Ghebremeskel
  • Publication number: 20180353426
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
    Type: Application
    Filed: January 8, 2018
    Publication date: December 13, 2018
    Inventors: Lon T. Spada, Alazar N. Ghebremeskel, Michael R. Robinson
  • Publication number: 20180271878
    Abstract: Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventors: Alazar N. Ghebremeskel, Michael R. Robinson
  • Patent number: 9980974
    Abstract: Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: May 29, 2018
    Assignee: Allergan, Inc.
    Inventors: Alazar N. Ghebremeskel, Michael R. Robinson
  • Patent number: 9861576
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: January 9, 2018
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, Alazar N. Ghebremeskel, Michael R. Robinson
  • Publication number: 20170100334
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 13, 2017
    Inventors: Lon T. Spada, Alazar N. Ghebremeskel, Michael R. Robinson
  • Publication number: 20170071853
    Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.
    Type: Application
    Filed: November 28, 2016
    Publication date: March 16, 2017
    Inventors: Michael R. Robinson, James A. Burke, Rhett M Schiffman, Alazar N. Ghebremeskel
  • Publication number: 20170056412
    Abstract: Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.
    Type: Application
    Filed: November 14, 2016
    Publication date: March 2, 2017
    Inventors: Alazar N. Ghebremeskel, Michael R. Robinson
  • Patent number: 9522113
    Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: December 20, 2016
    Assignee: Allergan, Inc.
    Inventors: Lon T. Spada, Alazar N. Ghebremeskel, Michael R. Robinson
  • Patent number: 9504696
    Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: November 29, 2016
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, James A. Burke, Rhett M. Schiffman, Alazar N. Ghebremeskel